American Association for Cancer Research
Browse
15417786mcr190589-sup-223472_1_supp_5677943_pvf5x4.jpeg (356.5 kB)

Supplementary Data 5 from Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition

Download (356.5 kB)
figure
posted on 2023-04-03, 17:28 authored by Teena Dhir, Christopher W. Schultz, Aditi Jain, Samantha Z. Brown, Alex Haber, Austin Goetz, Chunhua Xi, Gloria H. Su, Liang Xu, James Posey, Wei Jiang, Charles J. Yeo, Talia Golan, Michael J. Pishvaian, Jonathan R. Brody

Supplemental figure 5: (A) Loewe synergy plots for Mia PaCa2 and Panc-1 cells treated with abemaciclib with 5-florouracil (5-FU) or irinotecan. (B) Percent viability for various combination therapies, in Mia PaCa2 and Panc-1 cells, after treatment with abemaciclib and HuR or YAP1 inhibitors as shown. This is in correspondence to the Loewe synergism graphs shown in Figure 6A-B.

Funding

Newell Devalpine Foundation

NIGMS

National Institutes of Health

History

ARTICLE ABSTRACT

Mutation or promoter hypermethylation of CDKN2A is found in over 90% of pancreatic ductal adenocarcinomas (PDAC) and leads to loss of function of cell-cycle inhibitors p16 (INK4A) and p14 (ARF) resulting in unchecked proliferation. The CDK4/6 inhibitor, abemaciclib, has nanomolar IC50s in PDAC cell lines and decreases growth through inhibition of phospho-Rb (pRb), G1 cell-cycle arrest, apoptosis, and the senescent phenotype detected with β-galactosidase staining and relevant mRNA elevations. Daily abemaciclib treatments in mouse PDAC xenograft studies were safe and demonstrated a 3.2-fold decrease in tumor volume compared with no treatment (P < 0.0001) accompanying a decrease in both pRb and Ki67. We determined that inhibitors of HuR (ELAVL1), a prosurvival mRNA stability factor that regulates cyclin D1, and an inhibitor of Yes-Associated Protein 1 (YAP1), a pro-oncogenic, transcriptional coactivator important for CDK6 and cyclin D1, were both synergistic with abemaciclib. Accordingly, siRNA oligonucleotides targeted against HuR, YAP1, and their common target cyclin D1, validated the synergy studies. In addition, we have seen increased sensitivity to abemaciclib in a PDAC cell line that harbors a loss of the ELAVL1 gene via CRISP-Cas9 technology. As an in vitro model for resistance, we investigated the effects of long-term abemaciclib exposure. PDAC cells chronically cultured with abemaciclib displayed a reduction in cellular growth rates (GR) and coresistance to gemcitabine and 5-fluorouracil (5-FU), but not to HuR or YAP1 inhibitors as compared with no treatment controls. We believe that our data provide compelling preclinical evidence for an abemaciclib combination–based clinical trial in patients with PDAC. Our data suggest that abemaciclib may be therapeutically relevant for the treatment in PDAC, especially as part of a combination regimen inhibiting YAP1 or HuR.